Short answer · Medically reviewed summary · Last updated: 2026-05-08
Glioblastoma multiforme was first formally categorized in the early 20th century, evolving from a misunderstood "gliosarcoma" into the complex, aggressive primary brain tumor we recognize today. While historically considered a uniform diagnosis, modern medicine has transformed our understanding of Glioblastoma multiforme through molecular subtyping, shifting treatment from broad surgical resection toward personalized, genetics-driven protocols. When was Glioblastoma multiforme first described? The history of Glioblastoma multiforme dates back to the late 19th century, but it was not until 1926 that Percival Bailey and Harvey Cushing provided the definitive classification in their seminal work, A Classification of Tumors of the Glioma Group.
What is the history of Glioblastoma multiforme?
History of Glioblastoma multiforme: when and how it was discovered, and the milestones in research since, medically reviewed.
Glioblastoma multiforme was first formally categorized in the early 20th century, evolving from a misunderstood "gliosarcoma" into the complex, aggressive primary brain tumor we recognize today. While historically considered a uniform diagnosis, modern medicine has transformed our understanding of Glioblastoma multiforme through molecular subtyping, shifting treatment from broad surgical resection toward personalized, genetics-driven protocols.
When was Glioblastoma multiforme first described?
The history of Glioblastoma multiforme dates back to the late 19th century, but it was not until 1926 that Percival Bailey and Harvey Cushing provided the definitive classification in their seminal work, A Classification of Tumors of the Glioma Group. Before this, these tumors were often grouped under vague terms like "gliosarcoma" due to their varied, chaotic appearance under a microscope.
How has our understanding of the disease evolved?
For decades, Glioblastoma multiforme was treated as a single entity based purely on its histological appearance. The most significant shift occurred in 2016 and 2021, when the World Health Organization (WHO) updated its classification system to prioritize molecular markers over purely physical appearance. We now understand that Glioblastoma multiforme is a collection of distinct biological entities, each responding differently to therapy based on genetic signatures like IDH mutations and MGMT promoter methylation.
What were the major milestones in treatment development?
The treatment landscape has seen several pivotal breakthroughs that have extended life expectancy for many patients:
- 1970s: The introduction of corticosteroids to manage brain edema.
- 2005: The "Stupp Protocol" established the standard of care: maximal safe surgical resection followed by concurrent radiation and temozolomide chemotherapy.
- 2010s-Present: The emergence of Tumor Treating Fields (TTFields) and ongoing exploration of immunotherapy and precision medicine.
How did historical misconceptions change?
Historically, Glioblastoma multiforme was often viewed as a singular, uniform malignancy. We now know that the "multiforme" in the name refers to its striking cellular heterogeneity—meaning a single tumor can contain many different types of cells. Today, 85 members of the DiseaseMaps.org community share their experiences, helping to highlight that while Glioblastoma multiforme remains a formidable challenge, advocacy and data-sharing are accelerating the pace of research.
Next steps
- Consult with a neuro-oncologist to discuss comprehensive genomic profiling of your tumor.
- Join the DiseaseMaps.org community to connect with others currently navigating a Glioblastoma multiforme diagnosis.
- Review active clinical trials on ClinicalTrials.gov to see if precision medicine or immunotherapy options are available for your specific molecular subtype.
Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.
References
- National Institutes of Health (NIH) - Genetic and Rare Diseases Information Center (GARD)
- World Health Organization (WHO) Classification of Tumours of the Central Nervous System
- PubMed: "The History of Glioblastoma: From Histology to Molecular Biology"
- American Brain Tumor Association (ABTA)
